3 Stocks On The Rise – FRX, MEM and ESE

Stocks on the rise

After having a mix session, ASX was steady today with a flat close as at October 18, 2018 of 5942.4, Some of the stocks that turned out in green with significant rise in price are discussed in herein. While one is from telecommunication sector, two are from the health care sector. Let’s take a look at them.

FLEXIROAM LIMITED (ASX: FRX) – Compared to the corresponding 2018 half year, the company witnessed a solid growth in subscribers up by 64% and user base up by 170%. In the half year ended 30 September 2018, there has been a significant increase in cash receipts, rising to AUD$3.5 million up by 188%, as compared to the half year ended 30 September 2017, AUD$1.2 million. The company has a positive operating cash flow of AUD$84,000 in 2Q19. Through a private share placement in August 2018, successfully raised AUD$1.16 million. For the half year ended 30 September 2018, cash receipts totalled AUD$3.52 million, representing an increase of 188% over the previous corresponding half year mainly through improved consumer and corporate sales. The stock had a surge of 125% as at October 18, 2018, to trade at a market price of $0.063. Since last one year the stock has seen a performance change of -65.43%. [optin-monster-shortcode id=”swikrbu1d9j9aq0o4cko”]

MEMPHASYS LIMITED (ASX: MEM) – Operations in the first half of the financial year were funded with various loans. Memphasys finalised the financial year with an excess in working capital of $37,879 compared to 2017 deficiency of $2,356,669 and with net assets of $3,351,580 compared to 2017 net assets deficiency of $402,240. Cash and cash equivalents at end of the financial year was of $201,807 with no debt leaves the company in a decent balance sheet position. The Group made a net loss for the year ended 30 June 2018 of $401,159 compared to 2017 loss of $1,999,891. Memphasys’ strategy will continue to be focused on developing the Felix human IVF device, positioning it ready for market launch. The stock had a surge of 212.5% as at October 18, 2018, to trade at a market price of $0.050. Since last one 3 months the stock has seen a performance change of 6.67%.

ESENSE-LAB LTD (ASX: ESE) – The company reported revenue from continuing operations has decreased from USD $53,000 as at June 30, 2017 to USD $11,000 as at June 30, 2018. Net Loss for the period attributable to members, increased from $1,159,000 in 2017 to $1,192,000 in 2018. No dividend was declared, recommended and paid for the current year or was paid for the previous year. The cash and cash equivalents at the end of the financial year period decreased from $1,907,000 in 2017 to $951,000 in 2018. The stock had a surge of 53.846% as at October 18, 2018, to trade at a market price of $0.100. Since last one year the stock has seen a performance change of -75.00%.

 T R

FRX, MEM, ESE, Daily Price; Source: Thomson Reuters 

Dividend Stocks To Buy

The Income available from dividends remains attractive for many investors.

We take a look at the best yields on the market and assess what they say about a company’s prospect.

One Thing is certain, though, Australia interest rates are still low, making income difficult to come by and keeping the focus for many investors on high yielding stocks. Kalkine’s team of analysts bought you handpicked report for “Top 25 Dividend Stocks For 2018.”

ASX-relevant Special Reports are published year-round to provide a detailed analysis into an investing opportunity or a potential risk to your portfolio.

Click here to get your free report.


The advice given by Kalkine Pty Ltd and provided on this website is general information only and it does not take into account your investment objectives, financial situation or needs. You should therefore consider whether the advice is appropriate to your investment objectives, financial situation and needs before acting upon it. You should seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice. Not all investments are appropriate for all people. Kalkinemedia.com and associated websites are published by Kalkine Pty Ltd ABN 34 154 808 312 (Australian Financial Services License Number 425376). website), employees and/or associates of Kalkine Pty Ltd do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations.

Checkout our Free Dividend Stocks Report

Specially made for income-hungry investors, Invest in growing Franked Dividends an opportunity that should not be missed.

6 Cannabis Stocks under Investor’s Limelight…

Cannabis companies that sell both medicinal weed and recreational pot. Marijuana stocks to look at. Marijuana mergers and acquisitions. Dispensary data analytics. Upcoming marijuana IPO’s Those phrases have become increasingly common as marijuana legalization spreads.

Global spending on legal cannabis is expected to grow 230% to $32 billion in 2020 as compared to $9.5 in 2017, according to Arcview Market Research and BDS Analytics. As of June 29, 2018 the United States Marijuana Index, despite a lot of uncertainty around regulations, has over the past 1 year gained 71.49%, as compared to about 12% gain seen by the S&P 500.

Click here for your FREE Report